



# T Cell Lymphoma

## Xenograft Tumor Model

MODEL	NOMENCLATURE	HAIR	T CELLS	B CELLS	NK CELLS
SHrN <sup>®</sup>	NOD.Cg-Prkdc <sup>scid</sup> Hr <sup>hr</sup> /NCrHsd	No	Nonfunctional	Functional	Impaired

### MODEL

The SHrN<sup>®</sup> is a Hairless NOD.SCID Mouse developed by Harlan. Harlan became Envigo in 2015, then Envigo was acquired by Inotiv in 2021. The SHrN<sup>®</sup> is a triple-immunodeficient model with distinct benefits and excellent for tumor xenografts.


### CELL LINE

Human KARPAS-299 cells sourced from DSMZ (Number: ACC 31) were implanted into a cohort of SHrN<sup>®</sup> mice. Female mice at approximately 8 weeks of age were implanted with 1.0e7 cells with GFR Matrigel (1:1 dilution) into the subcutaneous space of the right flank.

### TUMOR GROWTH *IN VIVO*

The mice were maintained in a barrier under controlled environmental conditions. The mice consumed Teklad Global Rodent Diet 2914 (14% protein). Body weights were taken and tumor measurements were assessed with a caliper twice per week.

#### Tumor Growth Rate for KARPAS-299 Cells Inoculated into Female SHrN<sup>®</sup> Mice



Data shown as mean values; N=5  
Tumor growth study services conducted by Labcorp Drug Development